Press release
Natera Reports Fourth Quarter and Full Year 2022 Financial Results
AUSTIN, Texas--(BUSINESS WIRE)-- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today reported financial results for the fourth
About this update from Natera, Inc.
[{"type":"text","content":" AUSTIN, Texas--(BUSINESS WIRE)--\nNatera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today reported financial results for the fourth quarter and year ended December 31, 2022 and provided an update on recent business progress and financial outlook.\n\nRecent Accomplishments & Highlights\n\n\nGenerated total revenues of $217.3 million in the fourth quarter of 2022 compared to $173.0 million in the fourth quarter of 2021, an increase of 25.6%. Product revenues grew 28.2% over the same period.\n\n\nGenerated total revenues of $820.2 million in the year 2022 compared to $625.5 million in the year 2021, an increase of 31.1%. Product revenues grew 37.4% over the same period.\n\n\nProcessed approximately 559,700 tests in the fourth quarter of 2022, compared to approximately 438,800 tests processed in the fourth quarter of 2021, an increase of 27.6%.\n\n\nProcessed approximately 2,066,500 tests in the year 2022, compared to approximately 1,570,000 tests processed in the year 2021, an increase of 31.6%.\n\n\nPerformed over 196,000 oncology tests in the year 2022, representing an increase of 158% over 2021, with 40 published peer-reviewed studies for Signatera to date.\n\n\nGuiding 2023 total revenue of $980 million – $1 billion, reducing cash burn by approximately $150 million in 2023.\n\n\nSecured Medicare coverage for breast cancer, representing fifth coverage decision for Signatera.\n\n\nProspective, multi-site CIRCULATE study featured on the cover and as lead publication in the January 2023 issue of Nature Medicine, which demonstrated Signatera’s ability to predict chemotherapy benefit in colorectal cancer with 18-months of clinical follow-up.\n\n\nNew American College of Medical Genetics (ACMG) guideline supporting screening for 22q.11.2 deletion syndrome.\n\n\nNational Society of Genetic Counselors (NSGC) guideline recommending that expanded carrier screening be made available to all individuals considering reproduction and all pregnant pairs.\n\n\nUpdated International Society for Heart and Lung Transplantation (ISHLT) guidelines for heart transplant, including dd-cfDNA testing in a Class 1B recommendation.\n\n\nSeasoned healthcare executive Ruth Williams-Brinkley appointed to the Board, effective March 2, 2023.\n\n\n“We delivered another strong year in 2022, helping a record number of patients with their care,...